BiotechTube

Duloxetine

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Back Pain Lower Back Chronic

Conditions

Back Pain Lower Back Chronic

Trial Timeline

Sep 1, 2013 → Dec 1, 2014

NCT ID
NCT01914666

About Duloxetine

Duloxetine is a phase 3 stage product being developed by Shionogi for Back Pain Lower Back Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT01914666. Target conditions include Back Pain Lower Back Chronic.

What happened to similar drugs?

9 of 20 similar drugs in Back Pain Lower Back Chronic were approved

Approved (9) Terminated (3) Active (11)
✅tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
✅Diclofenac + CelecoxibPfizerApproved
✅PregabalinPfizerApproved
✅valdecoxib + diclofenacPfizerApproved
✅pregabalin and celecoxib + Placebo and celecoxibPfizerApproved
✅Tramadol Hydrochloride 50mg + Celebrex 200mgPfizerApproved
✅FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%PfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02335346Phase 3Completed
NCT01914666Phase 3Completed
NCT01621191Phase 3Completed

Competing Products

20 competing products in Back Pain Lower Back Chronic

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)Johnson & JohnsonPhase 3
40
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
AZD1940 + MidazolamAstraZenecaPhase 1
29
MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mgMerckPhase 3
32